COVID-19 in solid organ transplant recipients: initial report from national multicenter observational study «ROKKOR-recipient»
https://doi.org/10.15825/1995-1191-2020-3-8-17
Abstract
We herein present our initial report from «ROKKOR-recipient», a national multicenter observational study. The prevalence, risk factors, clinical manifestations and outcomes of the novel coronavirus disease 2019 (COVID-19) in solid organ transplant recipients receiving immunosuppressive therapy were investigated. The study enrolled 251 COVID-19 patients (220 kidney recipients, 7 liver recipients, 1 liver-kidney recipient, and 23 heart recipients). The subjects came from 20 regions in Russia. The symptoms, clinical presentation, imaging and lab test results, therapy and outcomes of COVID-19 were described. It was established that solid organ transplant recipients with COVID-19 have a higher risk of developing adverse events. Predictors of adverse events include associated cardiovascular diseases, pulmonary diseases, diabetes, and kidney failure. Symptoms of the disease include dyspnea, rash and catarrhal signs, as well as initial low blood oxygen saturation (SpO2 <92%), leukocytosis (white blood cell count >10 × 109/L), elevated creatinine levels (>130 μmol/L) and a marked decrease in glomerular filtration rate, requiring hemodialysis. Performing organ transplant surgery in COVID-19 does not increase the risk of adverse events but could save the lives of waitlisted terminally ill patients.
About the Authors
S. V. GautierRussian Federation
Moscow
A. O. Shevchenko
Russian Federation
Alexey Shevchenko.
Address: 1, Shchukinskaya str., Moscow, 123182, Russian Federation.
Phone: (495) 190-35-62.
O. M. Tsirulnikova
Russian Federation
Moscow
S. M. Khomyakov
Russian Federation
Moscow
O. N. Kotenko
Russian Federation
Moscow
V. E. Vinogradov
Russian Federation
Moscow
I. N. Abyzov
Russian Federation
Cheboksary
G. D. Avetisyan
Russian Federation
Smolensk
A. Yu. Anisimov
Russian Federation
Kazan
L. Yu. Artyukhina
Russian Federation
Moscow
M. T. Bekov
Russian Federation
Moscow
V. A. Berdinsky
Russian Federation
Moscow
V. S. Bogdanov
Russian Federation
Moscow
A. Yu. Bykov
Russian Federation
Novosibirsk
A. Yu. Vinokurov
Russian Federation
St. Petersburg
A. Yu. Goncharova
Russian Federation
Moscow
D. P. Evdokimov
Russian Federation
Krasnoyarsk
D. V. Ezersky
Russian Federation
Khabarovsk
V. E. Zagainov
Russian Federation
Nizhny Novgorod
V. M. Zakharevich
Russian Federation
Moscow
K. N. Zelenin
Russian Federation
Arkhangelsk
E. S. Ivanova
Russian Federation
Moscow
A. A. Kartashev
Russian Federation
Moscow
N. G. Kvadratova
Russian Federation
Moscow
I. G. Kim
Russian Federation
Moscow
N. N. Koloskova
Russian Federation
Moscow
V. L. Korobka
Russian Federation
Rostov-on-Don
I. R. Kurbanuglov
Russian Federation
Moscow
M. A. Lysenko
Russian Federation
Moscow
I. A. Miloserdov
Russian Federation
Moscow
Ya. G. Moisyuk
Russian Federation
Moscow
G. V. Nikolaev
Russian Federation
St. Petersburg
I. V. Ostrovskaya
Russian Federation
Moscow
N. Yu. Petrova
Russian Federation
Saratov
A. V. Petryaev
Russian Federation
Tula
A. V. Pinchuk
Russian Federation
Moscow
V. S. Platonov
Russian Federation
Khanty-Mansiysk
V. N. Poptsov
Russian Federation
Moscow
Z. A. Porchkhidze
Russian Federation
Moscow
D. A. Saydulaev
Russian Federation
Moscow
A. D. Sapozhnikov
Russian Federation
Volzhsky
S. B. Semchenko
Russian Federation
Tyumen
M. M. Skorobogatov
Russian Federation
Khanty-Mansiysk
V. Yu. Tereshchenko
Russian Federation
Omsk
N. F. Frolova
Russian Federation
Moscow
D. V. Khalikova
Russian Federation
Moscow
T. A. Khalilulin
Russian Federation
Moscow
References
1. WHO Coronavirus Disease (COVID-19) pandemic statistics [updated 2020 July 17]. Available from: https://covid19.who.int/region/euro/country/ru.
2. Li Q, Guan X, Wu P et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; 382: 1199–1207.
3. The Johns Hopkins Coronavirus Resource Center (CRC) [Internet]. COVID-19 mortality in the most affected countries [updated 2020 July 29]. Available from: https://coronavirus.jhu.edu/data/mortality.
4. Gori A, Dondossola D, Antonelli B, Mangioni D, Alagna L, Reggiani P et al. Coronavirus disease 2019 and transplantation: A view from the inside. Am J Transplant. 2020; 1939–1940. doi: 10.1111/ajt.15853.
5. Alberici F, Delbarba E, Manenti C et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV-2 pneumonia. Kidney International. 2020; 97 (6): 1083–1088. https://doi.org/10.1016/j.kint.2020.04.002.
6. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395: 473–475.
7. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. The Journal of Heart and Lung Transplantation. 2020; 39 (5): 405–407. https://doi.org/10.1016/j.healun.2020.03.012.
8. Junpeng Wang, Xin Li, Guanghui Cao, Xiaoqiang Wu, Zhiwei Wang, Tianzhong Yan. COVID-19 in a Kidney Transplant Patient. European Urology. 2020; 77 (6): 769–770.
9. Kamkin EG et al. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID 2019), Version 6 (04/28/2020). Ministry of Health of the Russian Federation; 2020. [In Russ]. URL: http://www.rdkb.med.cap.ru/UserFiles/main/sitemap/doc/2290dc80-f2c5-4cfd-ac5c-e81d87523d97/28042020_mr_covid-19_v6.pdf.
10. Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant. 2020; 39: 418–419.
11. Ren ZL, Hu R, Want ZW et al. Epidemiological and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: a descriptive survey report. J Heart Lung Transplant. 2020; 39: 412–417.
12. Carbajo-Lozoya J, Müller MA, Kallies S et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2020; 165 (1): 112–117. https://doi.org/10.1016/j.virusres.2012.02.002.
13. Dzhioeva ON, Drapkina OM. Osobennosti ul’trazvukovogo issledovaniya serdca u pacientov s novoi koronavirusnoi infekciei. Arterial’naya gipertenziya. 2020; 26 (3): 270–276. doi: 10.18705/1607-419X-2020-26-3-270-276.
14. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020; 141 (20): 1648–1655. doi.org/10.1161/CIRCULATIONAHA.120.046941.
15. Glybochko P, Fomin V, Avdeev S et al. Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia. Clin Pharmacol Ther. 2020; 29 (2): 21–29. [In Russ]. doi 10.32756/0869-5490-2020-2-21-29.
16. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; https://doi.org/10.1016/j.cell.2020.02.052.
17. Barbarash OL, Karetnikova VN, Kashtalap VV, Zvereva TN, Kochergina AM. New coronavirus disease (COVID-19) and cardiovascular disease. Complex Issues of Cardiovascular Diseases. 2020; 9 (2): 17–28. [In Russ]. doi: 10.17802/2306-1278-2020-9-2-17-28.
18. Poteshkina NG, Lysenko MA, Kovalevskaya EA, Fomina DS, Samsonova IV, Par shin VV et al. Cardiac damage in patients with COVID-19 coronavirus infection. Arterial Hypertension. 2020; 26 (3): 277–287. [In Russ]. doi: 10.18705/1607-419X-2020-26-3-277-287.
19. Barinov VE, Boyarintsev VV. Venous thrombotic complications as a satellite of the new coronavirus infection COVID-19. Kremlevskaya medicina. Klinicheskii vestnik. 2020; 2: 22–27. [In Russ]. doi: 10.26269/ayxs-2p77.
20. De Filippo O, D’Ascenzo F, Angelini F et al. Reduced rate of hospital admissions for ACS during COVID-19 outbreak in northern Italy. N Engl J Med. doi: 10.1056/NEJMc2009166.
21. Garcia S, Albaghdadi MS, Meraj PM et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020; 75 (22): 2871–2872. https://doi.org/10.1016/j.jacc.2020.04.011.
22. Chui KK, Rao ARN, Chan HLY, Hui AY. Impact of severe acute respiratory syndrome on liver transplantation service. Transplantation Proceedings. 2004; 36 (8): 2302–2303. https://doi.org/10.1016/j.transproceed.2004.08.018.
23. Winichakoon P, Chaiwarith R, Liwsrisakun C et al. Negative Nasopharyngeal and Oropharyngeal Swabs Do Not Rule Out COVID-19. Journal of Clinical Microbiology. 2020; 58 (5): e00297-20. doi: 10.1128/JCM.00297-20.
24. Ding Y, He L, Zhang Q et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004; 203: 622–630.
Review
For citations:
Gautier S.V., Shevchenko A.O., Tsirulnikova O.M., Khomyakov S.M., Kotenko O.N., Vinogradov V.E., Abyzov I.N., Avetisyan G.D., Anisimov A.Yu., Artyukhina L.Yu., Bekov M.T., Berdinsky V.A., Bogdanov V.S., Bykov A.Yu., Vinokurov A.Yu., Goncharova A.Yu., Evdokimov D.P., Ezersky D.V., Zagainov V.E., Zakharevich V.M., Zelenin K.N., Ivanova E.S., Kartashev A.A., Kvadratova N.G., Kim I.G., Koloskova N.N., Korobka V.L., Kurbanuglov I.R., Lysenko M.A., Miloserdov I.A., Moisyuk Ya.G., Nikolaev G.V., Ostrovskaya I.V., Petrova N.Yu., Petryaev A.V., Pinchuk A.V., Platonov V.S., Poptsov V.N., Porchkhidze Z.A., Saydulaev D.A., Sapozhnikov A.D., Semchenko S.B., Skorobogatov M.M., Tereshchenko V.Yu., Frolova N.F., Khalikova D.V., Khalilulin T.A. COVID-19 in solid organ transplant recipients: initial report from national multicenter observational study «ROKKOR-recipient». Russian Journal of Transplantology and Artificial Organs. 2020;22(3):8-17. https://doi.org/10.15825/1995-1191-2020-3-8-17